Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position

Amgen Inc. (NASDAQ:AMGN) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026.

Amgen Inc. (NASDAQ:AMGN) is also a staple in the 13F portfolio of Fisher Asset Management. The fund has held a small position in the company since early 2010. This position remained relatively stable through the decade and half since 2010. However, at the end of 2024 and in 2025, the fund has aggressively upped this stake. In the third and fourth quarter of 2025, the position has more than doubled compared to filings for the second quarter of 2025. At the end of the fourth quarter of 2025, the stake comprised close to 900,000 shares.

Latest reports suggest that Amgen Inc. (NASDAQ:AMGN) is the latest drug company that has agreed to sell medicines on TrumpRx, a government-run direct-to-consumer platform for pharmaceutical products. Per Fox News, a total of 54 prescription drugs from six pharma companies will be available on the site. The platform had launched last month with many drug giants agreeing to sell their products on the site for cash-paying customers as part of US President Donald Trump’s Most Favored Nation (MFN) drug pricing policy.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis, as well as Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers.

While we acknowledge the risk and potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.